Inhibition of insulin- and insulin-like growth factor-I-stimulated growth of human breast cancer cells by 1,25-dihydroxyvitamin D3 and the vitamin D3 analogue EB1089

European Journal of Cancer

Volumn 32, Issue 5, 1996, Pages 842-848

  Vink Van Wijngaarden, T ^a   Pols, H A P ^a   Buurman, C J ^a   Birkenhager J C ^a   Van Leeuwen, J P T M ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

1,25 dihyroxyvitamin D3; Breast cancer; C FOS; EB1089; Insulin; Insulin like growth factor I; MCF 7; Vitamin D analogue

Indexed keywords

CALCITRIOL; COLECALCIFEROL DERIVATIVE; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE; SEOCALCITOL; SOMATOMEDIN C;

ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CONTROLLED STUDY; GROWTH INHIBITION; GROWTH STIMULATION; HUMAN; HUMAN CELL; ONCOGENE C FOS; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CALCITRIOL; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INSULIN; INSULIN ANTAGONISTS; INSULIN-LIKE GROWTH FACTOR I; PROTO-ONCOGENE PROTEINS C-FOS; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0029936950     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(95)00647-8     Document Type: Article

References (42)

1. Reichel H, Koeffler HP, Norman AW. The role of the vitamin D endocrine system in health and disease. N Engl J Med 1989, 320, 980-991.
2. Walters MR. Newly identified actions of the vitamin D endocrine system. Endocr Rev 1992, 13, 719-764.
3. 3 metabolites. Cancer Res 1983, 43, 4443-4447.
4. 3 inhibitory effect on the growth of two human breast cancer cell lines (MCF-7, BT-20). J Steroid Biochem 1986, 24, 373-376.
5. Colston KW, Berger U, Coombes RC. Possible role for vitamin D in controlling breast cancer cell proliferation. Lancet 1989, i, 188-191.
6. 3, hypercalcemia, and growth suppression of 7, 12-dimethylbenz-[a]anthracene-induced rat mammary tumors. Breast Cancer Res Treat 1992, 22, 133-140.
7. 3 and tamoxifen on the growth of MCF-7 and ZR-75-1 human breast cancer cells. Breast Cancer Res Treat 1993, 29, 161-168.
8. Bikle DD. Clinical counterpoint: vitamin D: new actions, new analogs, new therapeutic potential. Endocr Rev 1992, 13, 765-784.
9. Pols HPA, Birkenhäger JC, Van Leeuwen JPTM. Vitamin D analogues: from molecule to clinical application. Clin Endocrinol 1994, 40, 285-291.
10. Lippman ME, Dickson RB, Kasid A, et al. Autocrine and paracrine growth regulation of human breast cancer. J Steroid Biochem 1986, 24, 147-154.
11. Rosen N, Yee D, Lippman ME, Paik S, Cullen KJ. Insulin-like growth factors in human breast cancer. Breast Cancer Res Treat 1991, 18, 855-862.
12. Milazzo G, Giorgino F, Damante G, et al. Insulin receptor expression and function in human breast cancer cell lines. Cancer Res 1992, 52, 3924-3930.
13. Osborne CK, Clemmons DR, Arteaga CL. Regulation of breast cancer growth by insulin-like growth factors. Steroid Biochem Mol Biol 1990, 37, 805-809.
14. Cullen KJ, Yee D, Sly WS, et al. Insulin-like growth factor expression and function in human breast cancer. Cancer Res 1990, 50, 48-53.
15. Huff KK, Kaufman D, Gabbay KH, Spencer EM, Lippman ME, Dickson RB. Secretion of an insulin-like growth factor-I-related protein by human breast cancer cells. Cancer Res 1986, 46, 4613-4619.
16. Czech MP, Lewis RE, Corvera S. Multifunctional glycoprotein receptors for insulin and the insulin-like growth factors. CIBA Found Symp 1989, 145, 27-44.
17. Holly JMP, Martin JL. Insulin-like growth factor binding proteins: a review of methodological aspects of their purification, analysis and regulation. Growth Regul 1994, 4 (Suppl. 1), 20-30.
18. Figueroa JA, Yee D. The insulin-like growth factor binding proteins (IGFBPs) in human breast cancer. Breast Cancer Res Treat 1992, 22, 81-90.
19. Figueroa JA, Jackson JG, McGuire WL, Krywicki RF, Yee D. Expression of insulin-like growth factor binding proteins in breast cancer correlates with estrogen receptor status. J Cell Biochem 1993, 52, 196-205.
20. McGuire SE, Hilsenbeck SG, Figueroa JA, Jackson JG, Yee D. Detection of insulin-like growth factor binding proteins (IGFBPs) by ligand blotting in breast cancer tissues. Cancer Lett 1994, 77, 25-32.
21. 3 analogs and tamoxifen. Cancer Res 1994, 54, 5711-5717.
22. Wilding G, Lippman ME, Gelmann EP. Effects of steroid hormones and growth factors on protooncogene c-fos expression in human breast cancer cells. Cancer Res 1988, 48, 802-805.
23. Mehmet H. Regulation of c-fos expression in Swiss 3T3 cells: an interplay of multiple signal transduction pathways. Br Med Bull 1991, 47, 76-86.
24. Anderson NG. MAP kinases - ubiquitous signal transducers and potentially important components of the cell cycling machinery in eukaryotes. Cell Signal 1992, 4, 239-246.
25. Binderup E, Calverley MJ, Binderup L. Synthesis and biological activity of 1α-hydroxylated vitamin D analogues with polyunsaturated side chains. In Norman AW, Bouillon R, Thomasset M, eds. Vitamin D: Gene Regulation, Structure-Function Analysis and Clinical Application: Proc. 8th Workshop on Vitamin D. Berlin, Walter de Gruyter, 1991, 192-193.
26. Francis GL, Ross M, Ballard FJ, et al. Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. J Mol Endocrinol 1992, 8, 213-223.
27. Ballard FJ, Francis GL, Ross M, Bagley CJ, May B, Wallace JC. Natural and synthetic forms of insulin-like growth factor-I (IGF-I) and the potent derivative, destripeptide IGF-I: biological activities and receptor binding. Biochem Biophys Res Commun 1987, 149, 398-404.
28. Maassen JA, Klinkhamer MP, Odink RJH, et al. Improper expression of insulin receptors on fibroblasts from a lepechaun patient. Eur J Biochem 1988, 172, 725-729.
29. Van den Berghe N, Ouwens DM, Maassen JA, Van Mackelenbergh MGH, Sips HCM, Krans HM. Activation of the ras/mitogen activated protein kinase signaling pathway alone is not sufficient to induce glucose uptake in 3T3-L1 adipocytes. Mol Cell Biol 1994, 14, 2372-2377.
30. Van Straaten F, Müller R, Curran T, Van Beveren C, Verma IM. Complete nucleotide sequence of a human c-onc gene: deduced amino acid sequence of the c-fos protein. Proc Natl Acad Sci USA 1983, 80, 3183-3187.
31. Benham FJ, Hodgkinson S, Davies KE. A glyceraldehyde-3-phosphate dehydrogenase pseudogene on the short arm of the human X chromosome defines a multigene family. EMBO J 1984, 3, 2635-2640.
32. Van der Burg B, Rutteman GR, Blankenstein MA, De Laat SW, Van Zoelen EJJ. Mitogenic stimulation of human breast cancer cells in a growth factor-defined medium: synergistic action of insulin and estrogen. J Cell Physiol 1988, 134, 101-108.
33. Stewart AJ, Johnson MD, May FEB, Westley BR. Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J Biol Chem 1990, 265, 21, 172-21, 178.
34. Thorsen T, Lahooti H, Rasmussen M, Aakvaag A. Oestradiol treatment increases the sensitivity of MCF-7 cells for the growth stimulatory effect of IGF-I. J Steroid Biochem Mol Biol 1992, 41, 537-540.
35. Colston KW, Mackay AG, James SY, Binderup L. EB1089: a new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro. Biochem Pharmacol 1992, 44, 2273-2280.
36. Mathiasen IS, Colston KW, Binderup L. EB1089, a novel vitamin D analogue, has strong antiproliferative and differentiation inducing effects on cancer cells. J Steroid Biochem Mol Biol 1993, 46, 365-371.
37. 3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia. Endocrinology 1991, 129, 832-837.
38. Rohlik QT, Adams D, Kull FC Jr, Jacobs S. An antibody to the receptor for insulin-like growth factor I inhibits the growth of MCF-7 cells in tissue culture. Biochem Biophys Res Commun 1987, 149, 276-281.
39. Pap V, Pezzino V, Costantino A, et al. Elevated insulin receptor content in human breast cancer. J Clin Invest 1990, 86, 1503-1510.
40. Dideriksen LH, Jorgensen LN, Drejer K. Carcinogenic effect on female rats after 12 months administration of the insulin analogue B10 Asp. Diabetes 1992, 41 (Suppl. 1), 143A (Abstract).
41. 3. Mol Cell Endocrinol 1989, 6, 189-198.
42. 3 analogs correlates with inhibition of DNA synthesis and reduced calmodulin concentration. Lab Invest 1986, 55, 269-275.